Xeris Biopharma Holdings, Inc. XERS
We take great care to ensure that the data presented and summarized in this overview for Xeris Biopharma Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding XERS
View all-
Black Rock Inc. New York, NY10.3MShares$75.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$71.7 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.84MShares$28 Million0.01% of portfolio
-
State Street Corp Boston, MA3.78MShares$27.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.65MShares$26.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.64MShares$26.6 Million0.0% of portfolio
-
Qube Research & Technologies LTD London, X03.09MShares$22.6 Million0.02% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.93MShares$21.4 Million0.01% of portfolio
-
Nuveen, LLC Charlotte, NC2.6MShares$19 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY2.27MShares$16.6 Million0.0% of portfolio
Latest Institutional Activity in XERS
Top Purchases
Top Sells
About XERS
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Insider Transactions at XERS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 13
2025
|
John Johnson Director |
SELL
Open market or private sale
|
Direct |
107,500
-11.42%
|
$752,500
$7.32 P/Share
|
|
Aug 12
2025
|
Dawn Halkuff Director |
SELL
Open market or private sale
|
Direct |
42,500
-26.98%
|
$297,500
$7.28 P/Share
|
|
Aug 01
2025
|
John Patrick Shannon Jr Director |
SELL
Payment of exercise price or tax liability
|
Direct |
36,918
-1.37%
|
$184,590
$5.38 P/Share
|
|
Aug 01
2025
|
Kevin Mc Culloch Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,651
-0.85%
|
$73,255
$5.38 P/Share
|
|
Jun 13
2025
|
Kevin Mc Culloch Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+1.44%
|
$100,000
$4.38 P/Share
|
|
Jun 04
2025
|
Marla Persky Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+24.1%
|
-
|
|
Jun 04
2025
|
Barbara Jean Anne Bormann Kennedy Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+24.1%
|
-
|
|
Jun 04
2025
|
John Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+5.05%
|
-
|
|
Jun 04
2025
|
Jeffrey W Sherman Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+18.91%
|
-
|
|
Jun 04
2025
|
Dawn Halkuff Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+24.1%
|
-
|
|
Jun 04
2025
|
Garheng Kong Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+18.93%
|
-
|
|
Apr 02
2025
|
Kevin Mc Culloch Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
733
-0.04%
|
$3,665
$5.15 P/Share
|
|
Mar 28
2025
|
James Aloysius Brady Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Mar 20
2025
|
Beth Hecht Officer |
SELL
Open market or private sale
|
Direct |
40,000
-2.87%
|
$200,000
$5.43 P/Share
|
|
Jan 31
2025
|
Beth Hecht Officer |
BUY
Grant, award, or other acquisition
|
Direct |
185,000
+11.72%
|
-
|
|
Jan 31
2025
|
Beth Hecht Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
144,284
-5.46%
|
$432,852
$3.56 P/Share
|
|
Jan 31
2025
|
John Patrick Shannon Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
800,000
+22.94%
|
-
|
|
Jan 31
2025
|
John Patrick Shannon Jr Director |
SELL
Payment of exercise price or tax liability
|
Direct |
221,500
-5.4%
|
$664,500
$3.56 P/Share
|
|
Jan 31
2025
|
Kevin Mc Culloch Officer |
BUY
Grant, award, or other acquisition
|
Direct |
185,000
+9.9%
|
-
|
|
Jan 31
2025
|
Kevin Mc Culloch Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
78,134
-2.51%
|
$234,402
$3.56 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.76M shares |
|---|---|
| Exercise of conversion of derivative security | 19.5K shares |
| Open market or private purchase | 25K shares |
| Open market or private sale | 190K shares |
|---|---|
| Payment of exercise price or tax liability | 855K shares |